Cypress Asset Management Inc. TX Reduces Position in iShares Nasdaq Biotechnology ETF (IBB)

Share on StockTwits

Cypress Asset Management Inc. TX lowered its position in iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) by 10.6% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 5,205 shares of the financial services provider’s stock after selling 615 shares during the period. Cypress Asset Management Inc. TX’s holdings in iShares Nasdaq Biotechnology ETF were worth $635,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in IBB. American Financial Network Advisory Services LLC boosted its position in iShares Nasdaq Biotechnology ETF by 15,963.3% during the third quarter. American Financial Network Advisory Services LLC now owns 7,871 shares of the financial services provider’s stock worth $960,000 after purchasing an additional 7,822 shares during the period. TRUE Private Wealth Advisors boosted its position in iShares Nasdaq Biotechnology ETF by 15.3% during the third quarter. TRUE Private Wealth Advisors now owns 3,640 shares of the financial services provider’s stock worth $444,000 after purchasing an additional 483 shares during the period. Longer Investments Inc. boosted its position in iShares Nasdaq Biotechnology ETF by 57.2% during the third quarter. Longer Investments Inc. now owns 23,637 shares of the financial services provider’s stock worth $2,882,000 after purchasing an additional 8,603 shares during the period. BB&T Corp boosted its position in iShares Nasdaq Biotechnology ETF by 24.6% during the third quarter. BB&T Corp now owns 2,571 shares of the financial services provider’s stock worth $314,000 after purchasing an additional 508 shares during the period. Finally, Parkside Investments LLC boosted its position in iShares Nasdaq Biotechnology ETF by 1.4% during the third quarter. Parkside Investments LLC now owns 35,342 shares of the financial services provider’s stock worth $4,309,000 after purchasing an additional 475 shares during the period. Hedge funds and other institutional investors own 64.65% of the company’s stock.

iShares Nasdaq Biotechnology ETF stock traded down $1.80 during trading hours on Friday, reaching $111.20. 158,130 shares of the company were exchanged, compared to its average volume of 1,893,287. iShares Nasdaq Biotechnology ETF has a 12 month low of $100.22 and a 12 month high of $122.97.

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, October 2nd. Stockholders of record on Thursday, September 27th were given a $0.0324 dividend. The ex-dividend date of this dividend was Wednesday, September 26th. This represents a $0.13 annualized dividend and a dividend yield of 0.12%.

iShares Nasdaq Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Featured Story: Fundamental Analysis

Institutional Ownership by Quarter for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Nasdaq Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Nasdaq Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Insider Buying: Wright Medical Group NV  Director Purchases 20,000 Shares of Stock
Insider Buying: Wright Medical Group NV Director Purchases 20,000 Shares of Stock
Snc-Lavalin Group Inc  Receives Average Rating of “Buy” from Brokerages
Snc-Lavalin Group Inc Receives Average Rating of “Buy” from Brokerages
Analysts Expect Amdocs Limited  Will Announce Quarterly Sales of $1.01 Billion
Analysts Expect Amdocs Limited Will Announce Quarterly Sales of $1.01 Billion
Wells Fargo & Co Reiterates Buy Rating for Halliburton
Wells Fargo & Co Reiterates Buy Rating for Halliburton
Enterprise Group  Reaches New 12-Month Low at $0.22
Enterprise Group Reaches New 12-Month Low at $0.22
Bird Construction  Sets New 52-Week Low at $6.14
Bird Construction Sets New 52-Week Low at $6.14


© 2006-2018 Ticker Report